

Complex neuropathic pain states

Rhian P Lewis
Indre Kriukelyte

Abstract

In this article we discuss complex neuropathic pain states: diabetic peripheral neuropathic pain (DPNP), phantom limb pain (PLP), central post-stroke pain (CPSP), and complex regional pain syndrome (CRPS). Pain in these conditions can often be severe, significantly affect quality of life and be resistant to current treatment options. Multidisciplinary assessment and treatment is essential.

Keywords Central post-stroke pain; complex regional pain syndrome; diabetic peripheral neuropathic pain; painful diabetic neuropathy; phantom limb pain

Royal College of Anaesthetists CPD Matrix: 2E03

Diabetic peripheral neuropathic pain (DPNP)^{1,2}

Painful diabetic neuropathy is pain arising as a direct consequence of abnormalities in the somatosensory system in diabetic patients. It is the most common cause of peripheral neuropathy, occurs in type 1 and type 2 diabetes, and can affect up to 50% of patients. However, the pain is often under recognized, and up to 40% of sufferers have never received treatment.

The risk is increased with poor glycaemic control, elevated triglycerides, high body mass index, smoking, hypertension, age and duration of diabetes. Initial treatment therefore includes blood glucose optimization, dietary assistance, smoking cessation, weight loss and regular exercise. Tight glucose control is much more effective at preventing neuropathy in patients with type 1 diabetes than in those with type 2.

Presentation

The most common presentation is sensory-motor distal symmetric polyneuropathy in which there is symmetrical sensory loss in the 'glove and stocking' distribution. A third of these patients will develop painful diabetic neuropathy, and it is more prevalent in type 2 diabetes than in type 1. Eight per cent of patients with type 2 have neuropathy at the time of diagnosis. DPNP usually starts as a distal, symmetrical shooting or stabbing pain (with associated paraesthesia) which gradually ascends. It typically increases at rest or at night. Pain may also occur with focal mono- or multi-neuropathies (e.g. ulnar or lateral

Rhian P Lewis MBChB FRCA FFPM is a Consultant in Anaesthetics and Pain Management at Ysbyty Gwynedd, Bangor, Wales, UK. Conflicts of interest: none declared.

Indre Kriukelyte MB ChB is an Advanced Pain Trainee at Ysbyty Gwynedd, Bangor, Wales, UK. Conflicts of interest: none declared.

Learning objectives

After reading this article, you should be able to:

- diagnose complex neuropathic pain states
- explain pathophysiology
- select treatment options

cutaneous nerve of thigh) or as the 'burning feet syndrome' of small fibre neuropathy.

Simple assessment scales are valuable to screen for neuropathic pain, e.g. the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) and the Douleur Neuropathique Scale (DN4).

Diagnosis

Diagnosis is by history and clinical examination, documenting the area of sensory loss (pain with pin, touch with cotton wool, pressure with monofilament, temperature with hot and cold water tubes), impaired vibration (tuning fork) and altered proprioception and reduced tendon reflexes. The symptoms are not in a dermatomal or single-nerve distribution. Allodynia (pain sensation from a normally non-painful stimulus such as touch or cold) and hyperalgesia (increased response to a stimulus that is normally painful) are common findings.

The most commonly performed diagnostic tests are nerve conduction studies (NCS) and skin biopsy. NCS can confirm damage to large myelinated fibres; the earliest changes noted are slowing of conduction velocity. Skin biopsy measures epidermal nerve fibre density, and is a sensitive measure of both diabetic and non-diabetic small fibre neuropathy. However DPNP remains mainly a clinical diagnosis.

Mechanism

DPNP reflects a complex interaction between hyperglycaemia-induced metabolic and biochemical changes and inadequate perfusion due to microvascular changes. Due to the deficit in axoplasmic transport it predominantly affects the longest axons. As with most neuropathic pain states, central mechanisms are also important; distal abnormalities with spontaneous impulses lead to central sensitization, alterations in sodium and calcium channels, and loss of descending inhibition.

Treatment³

Initial pharmacological treatment (NICE 2013)⁴ should be a choice of amitriptyline, duloxetine, gabapentin or pregabalin. If the initial treatment is not effective or not tolerated, one of the remaining three drugs should be offered, and with no improvement drugs should be switched again. Tramadol should only be used if acute rescue therapy is needed. Capsaicin cream may be useful if oral treatment cannot be tolerated, although pain on application may be a problem. Capsaicin 8% patch (Quetenza) has recently been approved for use in DPNP. Lidocaine patches can be used for focal pain but are less valuable for diffuse neuropathy because the maximum area of application may be too small.

Opioids should be administered only if multiple first-line agents have been ineffective – oxycodone, morphine, tramadol, and tapentadol significantly improve pain in DPNP.

Phantom limb pain (PLP)^{5–7}

Amputation of a limb frequently results in non-painful phantom sensations, stump pain and phantom limb pain.

Non-painful sensations include a specific shape, position or movement of the limb, and sensations of warmth or cold, itching, tingling or paraesthesia are common. The phenomenon of ‘telescoping’ occurs when the distal part of the missing limb is felt to recede towards the stump, and probably occurs due to alterations within the somatosensory cortex.

Stump pain occurring immediately after amputation is acute nociceptive pain and usually resolves after a few weeks, but a more long-lasting stump pain can persist and may be linked to the development of PLP. It is therefore essential that it is well-managed.

Presentation

PLP occurs in up to 80% of amputees and may be exacerbated by many physical (e.g. temperature changes) and psychological (e.g. stress) factors. It is usually described as stabbing, throbbing, burning, or cramping, and commonly starts in the first week, although it can also develop years later. Risk factors are: pre-amputation pain, presence of persistent stump pain, bilateral limb amputations and lower limb amputations. It is less common in children and those with a congenitally absent limb.

The pain may be constant but of varying intensity in some amputees; others experience intermittent unpredictable incidences of high-intensity pain. Its duration is similarly unpredictable, resolving in months or persisting for decades. Pain for longer than 6 months has a poor prognosis for spontaneous improvement.

Mechanism

Peripheral mechanisms alter the afferent nerve supply to the central nervous system and include an inflammatory reaction and a process where free endings of A δ and C fibres sprout, forming a neuroma with resultant altered sodium channel function, reduced activation thresholds, and spontaneous discharge, leading to sensitization.

Further anatomical reorganization within the spinal cord occurring after peripheral nerve injury includes degeneration of unmyelinated C fibres that normally synapse in lamina 1 and 2 in the dorsal horn, and sprouting of connections between larger myelinated A β -fibres that are normally involved in touch, pressure and proprioception (normally in lamina 3 and 4) into lamina 1 and 2, thus resulting in non-painful stimuli being experienced as painful (allodynia). Central sensitization of dorsal horn cells occurs in response to the increased barrage of painful stimuli from the amputation site, and is responsible for the resultant hyperalgesia. During this process, there is also an increase in activity at *N*-methyl-D-aspartate (NMDA) receptors mediated by neurotransmitters such as substance P, tachykinins and neurokinins, and aspects of the central sensitization can be reduced by NMDA receptor antagonists.

Centrally, cortical reorganization has been demonstrated (e.g. the somatosensory cortex corresponding to the missing limb appears to receive sensory information from other areas

of the body that synapse at adjacent areas on the somatosensory cortex). The degree of cortical reorganization appears to be directly related to the degree of phantom pain, and imaging studies have correlated greater extent of somatosensory cortex changes with more intense phantom limb experience.

Treatment

Pre-amputation pain intensity is a significant predictor of PLP, but pre-emptive analgesia (e.g. epidural/specific nerve blockade with local anaesthetic or use of ketamine) has not reliably been shown to reduce PLP. However, multimodal balanced analgesic regimes are vital for postoperative pain and stress reduction, and since the onset of phantom pain is often in the first 7 days consideration could also be given to the use of additional anti-neuropathic medication at this time. There is recent experience that using continuous perineural blockade for a minimum of 80 hours may reduce the likelihood of PLP.

Revision of the stump is only indicated if there is specific localized pathology.

Anti-neuropathic medication is appropriate and tricyclics and gabapentinoids should be the first line. There is some evidence for the use of opioids.

Heat and cold, ultrasound, acupuncture, transcutaneous electrical nerve stimulation, massage, and alteration of the prosthesis have been used successfully. Mirror-box therapy has been used to good effect for symptoms involving pain due to involuntary movements and spasm of the phantom. The mirror is placed vertically so that it is possible to visualize the unclenching of the affected limb when the unaffected limb is moved appropriately.

Psychological techniques involving explanation and reassurance as well as CBT have been reported as beneficial.

Central post-stroke pain (CPSP)^{8,9}

CPSP (originally called thalamic pain syndrome) results from a primary lesion or dysfunction of the central nervous system following a stroke. It has a prevalence of 8–35% and can occur as early as the first month following stroke or some years later. The most common is 3–6 months. Risk factors include a young age, previous depression, smoking, and increased stroke severity. It is more common after ischaemic strokes and often interferes with rehabilitation and quality of life. It is usually on the contralateral side to the stroke, which can be anywhere within the spinothalamic pathway, although lateral medullary (25% incidence) and ventroposterior thalamic (incidence 11–59%) infarctions appear to have the highest incidence. The incidence in non-lateral medullary, non-thalamic stroke is 2–8%. Strokes affecting the right side are more commonly associated with pain. Following lateral medullary infarction pain can involve one side of the face and contralateral body and limbs, while in thalamic lesions pain is more commonly hemibody.

Presentation

CPSP is characterized by an intense spontaneous or evoked pain localized in the affected extremities. Onset is often gradual

and can coincide with improvements in sensory loss. It is typically constant and often made worse by touch, movement, emotions, and temperature changes. It is often described as constant burning or aching, with paraesthesia and intolerable intermittent stabbing which can be severe and debilitating. Allodynia and/or hyperalgesia are usually present. Pain occurs in decreasing order of frequency in arm, leg, trunk and face: the most common is hemibody. There may often be little motor weakness, but more subtle neurological deficits are common (60%). Many patients (at least 50%) report disturbed sleep, fatigue and stress with relationships, and these aspects and the attendant anxiety or depression (87%) need to be addressed.

Mechanism

Dysfunction of the spinothalamic cortical pathways is essential for the development of CPSP, and examination usually reveals abnormal temperature sensations and pinprick sensory loss, although somatosensory deficits do not always result in CPSP. A secondary factor may be denervation hypersensitivity (loss of inhibitory input) with resultant spontaneous discharges in thalamic and central neurones that have lost normal inhibitory input (central disinhibition).

Treatment

Treatment is often inadequate and the evidence base remains limited. Current hypotheses state that sodium channels are important in central pain states; studies have shown efficacy for intravenous lignocaine, lamotrigine, amitriptyline and carbamazepine. Noradrenergic system manipulations can be of value. Activation of central NMDA receptors is also a possible mechanism, and there is some evidence of the value of ketamine for short-term pain relief.

Amitriptyline and lamotrigine are regarded as first-line drugs: in clinical practice amitriptyline is usually better tolerated. Gabapentin or pregabalin are appropriate second-line drugs. Evidence for the use of phenytoin and topiramate is inconclusive. Carbamazepine is minimally effective and opioids are usually ineffective.

Invasive motor cortex stimulation (an electrode overlying the primary motor cortex) and deep brain stimulation (stimulation of the somatosensory thalamus and peri-ventricular grey matter) producing a non-painful paraesthesia in the painful area should only be considered in drug-resistant CPSP, and may help 20–50% of patients. Non-invasive transcranial magnetic stimulation of the motor cortex has been shown to be of value.

The pain appears to be alleviated with relaxation and worsened with emotional and physical stress, so that early psychological treatment options to modify negative thoughts and to teach coping strategies should be part of the treatment regimen to improve function and hence quality of life.

Complex regional pain syndrome (CRPS)^{10,11}

CRPS usually develops after trauma to a limb, and results in pain disproportionate to the inciting event. There are signs of vasomotor (constriction/dilatation of blood vessels), sudomotor

(sweat gland dysfunction), inflammatory and trophic changes which lead to severe limitation in function of the limb. Transient minor features are common. Incidence of CRPS is 26/100,000 life years and is more common in females. Thirty per cent of patients recover, 54% are stable and 15% do not improve within a 6-year period from disease onset. Early treatment aimed at restoration of function is essential to prevent secondary problems related to disuse of the limb.

Diagnosis is clinical, via the Budapest criteria (See [Appendix 1](#)).

Presentation

Typically, CRPS presents as a painful, erythematous, oedematous limb. Patients report temperature and sweating abnormalities, and allodynia is common (even wearing clothes causes pain). The joints are stiff, and movements are limited due to swelling and pain. There may be osteoporosis on X-ray or bone scan. It is also possible for the limb to be cold and blue, and the skin dry. Patients often neglect the limb further, compounding the disuse due to pain.

CRPS can be divided into two types: type 1 (most common) with no major nerve injury, and type 2 with damage to a major nerve. Management is identical in either case.

Mechanism

Possible pathophysiological mechanisms include classic and neuropathic inflammation, complex sympathetic dysregulation with regional autonomic changes, central sensitization, cortical reorganization and an autoimmune state.

Treatment

The uncertainty surrounding the mechanism has led to numerous treatment options based on the above possibilities. Traditional regional sympathetic blockade with guanethidine, for example, has not been shown to be effective in randomized controlled trials and there is limited evidence on the use of ketamine. More recently, treatment with intravenous immunoglobulins that have anti-inflammatory effects and the immune-modulating effect of bisphosphonates have been reported as beneficial.

CRPS is a biopsychosocial condition that requires prompt diagnosis with early multidisciplinary treatment. CRPS is not specifically associated with a previous history of psychological problems, but as with every pain condition psychosocial yellow flags are relevant.

Early physiotherapy may prevent progression of symptoms and bisphosphonates (pamidronate 60 mg by infusion) may be considered within the first 6 months of symptom onset.

Current recommendations (Royal College of Physicians 2012) include four pillars of treatment:

1. Patient education with information regarding CRPS, and instructions to attend to the limb with frequent gentle touching and encouragement of movement.
2. Neuropathic pain medication, particularly tricyclic antidepressants and gabapentinoids, can help with rehabilitation. Lidocaine 5% plasters may be helpful.
3. Physiotherapy, including desensitization (touch and massage to make the skin feel more normal), gradual weight

bearing, and fine motor exercises. This also aims to prevent stiffness and contractures. Patients often disregard the limb, and treatments such as computer-based graded motor imagery, which aims to train the brain to recognize the limb, and also mirror-box therapy, where the reflected movements of the unaffected limb are perceived by the brain as belonging to the affected limb, are valuable.

4. Cognitive behavioural therapy-based pain management to improve coping skills, management of anxiety and depression, and any counterproductive behaviour patterns.

Longer-term treatment may involve self-help groups and possible therapist support as needed.

Spinal cord stimulation (SCS) has been approved by NICE for CRPS where other treatments have not shown benefit, although the effect of SCS diminishes with time.

Conclusion

All neuropathic pain medication requires the application of the general principle of starting at a low dose, with slow titration upwards to an adequate dose, followed by assessment of efficacy and then withdrawal if unsatisfactory. Multiple medications with different mechanisms are often needed, with careful titration to avoid side effects. It needs to be recognized that a pain reduction of 30–50% is a good outcome for most available drugs.

Multidisciplinary assessment and support is vital to improve quality of life for patients with symptoms that are difficult to treat. Patients will experience depression, anxiety, fatigue and sleep disturbances, all of which adversely affect relationships, enjoyment of life and self-esteem. Treatment options need to be discussed with patients, taking into account their concerns and expectations and including the impact of pain on their daily activities. ◆

Sensory: Allodynia (to light touch, temperature sensation and/or deep somatic pressure and/or joint movement) and/or hyperalgesia (to pinprick). Sign? Symptom? (Note that hyperaesthesia qualifies as a symptom.)

Vasomotor: Temperature asymmetry and/or skin colour changes and/or skin colour asymmetry. Sign? (Note that temperature asymmetry must be >1 °C.) Symptom?

Sudomotor/oedema: Oedema and/or sweating changes and/or sweating asymmetry. Sign? Symptom?

Motor/trophic: Decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair/nail/skin). Sign? Symptom?

Box 1

Appendix 1

Budapest clinical diagnosis criteria for CRPS (based on Gantý and Chawla 2014)

- A. The patient has **continuing pain** which is disproportionate to the inciting event.
- B. The patient has at least one sign (you can see or feel a problem) in **two or more** categories in **Box 1**.
- C. The patient reports at least one symptom (the patient reports a problem) in **three or more** categories in the box below.
- D. **No other diagnosis** can better explain the signs and symptoms.

REFERENCES

- 1 Peltier A, Goutman SA, Callaghan BC. Painful diabetic neuropathy. *BMJ* 2014; **348**: g1799.
- 2 Rajan RS, de Gray L, George E. Painful diabetic neuropathy. *Contin Educ Anaesth Crit Care Pain* 2014; **14**: 230–5. <https://doi.org/10.1093/bjaceaccp/mkt063>.
- 3 Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. *Pain* 2010; **150**: 573–81. <https://doi.org/10.1016/j.pain.2010.06.019>.
- 4 NICE. Neuropathic pain in adults: pharmacological management in non-specialist settings. 2013. Available at: <http://www.nice.org.uk/guidance/CG173> (accessed 2 Mar 2016).
- 5 Jackson MA, Simpson KH. Pain after amputation. *Contin Educ Anaesth Crit Care Pain* 2004; **4**: 20–3. <https://doi.org/10.1093/bjaceaccp/mkh007>.
- 6 Neil MJE. Pain after amputation. *BJA Educ* 2016; **16**: 107–12. <https://doi.org/10.1093/bjaed/mkv028>.
- 7 Nikolajsen L, Jensen TS. Phantom limb pain. *Br J Anaesth* 2001; **87**: 107–16.
- 8 Harrison RA, Field TS. Post stroke pain: identification, assessment and therapy. *Cerebrovasc Dis* 2015; **39**: 190–201. <https://doi.org/10.1159/000375397>.
- 9 Klit H, Finnerup NB, Jensen TS. Central post-stroke pain: clinical characteristics, pathophysiology, and management. *Lancet Neurol* 2009; **8**: 857–68.
- 10 Royal College of Physicians. Complex regional pain syndrome in adults: UK guidelines for diagnosis, referral and management in primary and secondary care. 2012. Available at: <https://www.rcplondon.ac.uk/guidelines-policy/pain-complex-regional-pain-syndrome> (accessed 2 Mar 2016).
- 11 Gantý P, Chawla R. Complex regional pain syndrome: recent updates. *Contin Educ Anaesth Crit Care Pain* 2014; **14**: 79–84. <https://doi.org/10.1093/bjaceaccp/mkt043>.